So, unsurprisingly MGI have announced their intent to re-enter the US sequencing market. They appear to be timing the release of their instrument to coincide with the expiration of key Illumina (Solexa) IP. As reported by GenomeWeb: “According to MGI,
MGI (and Ultima Genomics)
MGI (and Ultima Genomics)
MGI (and Ultima Genomics)
So, unsurprisingly MGI have announced their intent to re-enter the US sequencing market. They appear to be timing the release of their instrument to coincide with the expiration of key Illumina (Solexa) IP. As reported by GenomeWeb: “According to MGI,